Nanoemulsified Artemisinin - Detox Supplement | Quicksilver Scientific
Quicksilver Scientific
1376 Miners Dr. Lafayette, CO 80026
Phone: (303) 531-0861 Hours: Mon-Fri, 10:00 AM - 5:00 PM
Quicksilver Scientific LLC Medical & Health United States Are you looking for a scientifically advanced health supplement wholesaler? We sell mercury detoxification and heavy metal tests as well as liposomal products. Monday to Friday: 08:00AM-5:00PM


This email address is being protected from spambots. You need JavaScript enabled to view it.


Quicksilver Delivery System
4 oz. (120 mL)

Artemisinin is an active constituent of the plant Artemisia annua, also known as sweet wormwood or Qinghaosu. Artemisinin is a sesquiterpene endoperoxide lactone, and the biological mechanism of action may be attributable to the generation of carbon-centered free radicals via heme-mediated or mitochondrial activated degradation of endoperoxidase bridges.1,2 Sesquiterpene lactones are secondary metabolites of plants that play an important role as attractants, deterrents, and antifeedants simultaneously.3 They are bitter compounds, and as such may impact digestion in a manner similar to digestive bitters. Artemisinin and its derivatives have been widely studied for their effects against Plasmodium falciparum, the protozoan parasite which causes malaria.4 Artemisinin-based combination therapies are recommended by the World Health Organization as first-line treatment for uncomplicated malaria in endemic regions.5 Artemisinin may impact the flora of the digestive system, genitourinary tract, and beyond,* having activity against microbes including Helicobacter pylori, Escherichia coli UPEC, Staphylococcus aureus, and Pseudomonas aeruginosa.6,7 It also may impact biofilms which make infections such as Candida albicans resistant to treatment.8

Because of the low bioavailability of traditional oral formulations of artemisinin, the use of derivatives such as artesunate (water-soluble) and artemether (oil-soluble) or alternate dosing strategies such as liposomes have been investigated. First-pass metabolism of artemisinin and these derivatives limit oral bioavailability to 30%.9 Liposomal delivery systems have been shown to lead to more stable artemisinin plasma concentrations,10 suggesting that they lead to an extended release and thereby prolonged systemic effect.* Additionally, more immediate effects have also been seen with liposomal formulations than conventional artemisinin.

Quicksilver's Delivery System brings the power of intravenous therapy into a convenient oral delivery.* Our Etheric Delivery™ improves upon liposomal technology with smaller, more stable, single-layer spheres made from the highest-grade ingredients available. This liposomal delivery system not only more directly delivers therapeutic agents to lymphatic circulation in the body,* but also provides phospholipids. Phospholipids form the external sphere of the liposomal package and are important for cellular membranes,11 ensuring proper function for the absorption of nutrients and the excretion of cellular waste products and toxins.*

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

General Suggested Usage: Use 1 tsp (5ml) 1 to 3 times per day as directed by your health practitioner. Best used in a cycle of 10 days on, and 4 days off. It is advisable to monitor liver function enzymes (LFT's) during usage. May be taken directly by mouth or mixed into water or juice (grapefruit juice is best). Store refrigerated and use within 60 days of opening


  1. Meshnick SR. Int J Parasitol. 2002 Dec;32:1655-60.
  2. Sun C, et al. Microb Cell. 2015;2:14-25.
  3. Rodriguez E, et al. Phytochemistry. 1976 Jan;15:1573-80.
  4. White NJ. Science. 2008 Apr;320:330-4.
  5. WHO guidelines for the treatment of malaria. Geneva: World Health Organization, 2006.
  6. Bilia AR, et al. Evid Based Complement Alternat Med. 2014;2014:159819.
  7. Goswami S, et al. Antimicrob Agents Chemother. 2012;56:4594-607.
  8. De Cremer K, et al. Antimicrob Agents Chemother. 2015 Jan;59(1):421-6.
  9. Medhi B, et al. Pharmacology. 2009;84:323-32.
  10. Isacchi B, et al. Eur J Pharm Biopharm. 2012 Apr;80:528-34.
  11. Spector AA, Yorek MA. J Lipid Res. 1985 Sep;26(9):1015-35.